Bristol-Myers Squibb Looks To Feed Oncology Pipeline With New Protein Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Discovery and development deal could be worth up to $1.3 billion for Waltham, Mass.-based Adnexus.